# About NAD Pharmacy: An Independent NAD+ Research Digest

> NAD Pharmacy is an independent editorial project that publishes plain-English summaries of the peer-reviewed research on NAD+ and its precursors. Not a clinic, not a vendor, not a prescription.

An independent editorial project that pins the published NAD+ research to the wall and reads it straight.

## An independent research digest

NAD Pharmacy is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ and its precursors, NMN and NR. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, compound, infuse, or distribute any product. Our work is editorial commentary on publicly available science.

The board metaphor is the whole method: each study, each enzyme, each precursor gets its own pinned card, the confirmed findings are marked as confirmed, and the gaps are flagged in plain sight rather than smoothed over. We lead with what trials actually measured and attribute every quantitative claim to its source.

## Why "Pharmacy" is a register, not a service

The word "pharmacy" in our name is editorial framing — the position of a formulary noticeboard that reads the record of what the literature shows. It is not a claim that this site dispenses, prescribes, compounds, or sells anything, and it is not a clinic, a telehealth service, or a storefront. NAD+ is not a prescription medicine; it is sold as a dietary supplement, and the injectable route is a compounded, unapproved wellness therapy. We summarize the research on all of it without offering, recommending, or selling any of it.

If you are looking to buy or receive a product, this is the wrong place — there is nothing here to purchase. What is here is a careful reading of the science.

## How we handle accuracy

We keep the distinctions that the field most often blurs. NAD+ is not the same as its precursors, and we never describe an oral NMN or NR trial as "taking NAD+." We report the contested FDA position on NMN's supplement status as a marketplace dispute, not as a ban. We present IV NAD+ as an unapproved compounded therapy with documented quality risks, including the FDA Class I endotoxin recall. And we describe only what specific cited studies measured — never that NAD+ treats, reverses, cures or prevents any disease. Where the evidence is rodent-only or preliminary, we say so.

---

A pinned-up research board on NAD+ — the redox coenzyme and its precursors NMN and NR tacked to their studies, the dose-dependent blood-NAD+ data marked confirmed and the unproven human endpoints flagged in red, with no clinic behind the board and nothing here infused, dispensed, or sold.